Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab added to statin plus ezetimibe for carotid plaque stabilization in acute coronary syndrome
ChiCTR2100054126Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of evolocumab in acute coronary syndrome (ACS), dyslipidemia and atherosclerosis (2 arms), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Carotid plaque fibrous cap thickness. Started May 2021; status: recruiting.
02
Drugs
evolocumab
03
Conditions
acute coronary syndrome (ACS)dyslipidemiaatherosclerosis
Beyond the preview
Go deeper on ChiCTR2100054126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054126.